Jagsonpal Pharmaceuticals Ltd. · NSE:JAGSNPHARM
Jagsonpal Pharmaceuticals — Q3 FY26 Earnings Presentation
25 slides from Jagsonpal Pharmaceuticals's earnings presentation, Jan 22, 2026
Slide 1: Exchange filing cover letter
Jagsonpal Pharmaceuticals Ltd Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar, -- ( ::.:&.mu • -~ Sakht Sector-18, Gurugram -122015, Haryana (India) Ph.: +91124 4406710; E-mail: info@jagsonpal.com; Website: www.jagsonpal.com A CSR Initiative lJAGSONPAL! CIN. : L7489
Slide 2: Jagsonpal announces Q3 & 9MFY26 Results
mu ' kht Jagsonpal Pharmaceuticals Ltd. announces Q3 & 9MFY26 Results 9MFY26 PAT up 12.5%, Cash balance of ₹ 1,757 Mn Gurugram, January 21st, 2026: Jagsonpal Pharmaceuticals Limited (BSE: 507789, NSE: JAGSNPHARM) today announced the unaudited financial results for the quarter ended December 31, 2025
Slide 3: About Jagsonpal Pharmaceuticals Limited
mu ' kht The company continues to maintain a strong liquidity position, with cash balances increasing by ₹152 Mn during the quarter to ₹1,757 Mn. This robust balance sheet, supported by strong fundamentals and a resilient brand portfolio, provides a solid foundation and the company is confident of s
Slide 4: Jagsonpal Pharmaceuticals Limited Q3 & 9MFY26
Jagsonpal Pharmaceuticals Limited Q3 & 9MFY26 Investor Presentation 21st January 2026 1
Slide 5: Safe Harbor
_,, Safe Harbor This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While t
Slide 6: Management Commentary
Management Commentary '' ,'' -,,,\ ,, _, We have reported stable performance during the nine months of FY26, even as we took focused initiatives to support growth. These should start reflecting in our performance from the ongoing quarter. Revenue increased 6% YoY to ₹2,230 Mn, while EBITDA (pre-ESOP
Slide 7: Q3 & 9MFY26 Highlights
Q3 & 9MFY26 Highlights 4 4
Slide 8: Highlights - Stable operations, Strong Balance Sheet
Highlights - Stable operations, Strong Balance Sheet 9MFY26 PAT up 12.5%, Cash balance up ₹ 152 Mn in Q3FY26 Consistent revenue trajectory Q3 revenue stood at ₹ 729 Mn, while 9M delivered a 6% YoY growth to ₹ 2,230 Mn. Operational discipline sustains EBITDA Margins Op. EBITDA of ₹ 166 Mn in Q3; Marg
Slide 9: Financial Highlights: 9MFY26
Financial Highlights: 9MFY26 Revenue from Operations Gross Profit & Margin (%) EBITDA & Margin* (%) PAT & Margin* (%) ■ 9MFY25 ■ 9MFY26 r ■ - ■ - ■ - ■ - ■ - ■ - ■ - ■ -. ■-■-■-■-■-■-■-. 2,230 2,102 1,424 359 1,354 503 482 319 64.4% 63.9% 22.6% 22.9% 15.2% 16.1% . . ■-■-■-■-■-■-■ .. L ■ -•-·-·-·-·-·
Slide 10: Financial Highlights: Q3FY26
Financial Highlights: Q3FY26 Revenue from Operations Gross Profit & Margin (%) EBITDA & Margin* (%) PAT & Margin* (%) ■ Q3FY25 ■ Q3FY26 .. ■-■-■-■-■-■-■ 740 729 475 465 171 125 166 115 64.2 % 63.7% 23.1% 22.7% 15.5% 17.1% I.. ■-■-■-■-■-■-■ --■-■-■-■-■-■-■• 11111 ■- ■ -■ - ■ - ■ - ■- . , "--■ - • - •
Slide 11: Income Statement
Income Statement (All values in ₹ Mn) Particulars Q3FY26 Q3FY25 % Change 9MFY26 9MFY25 % Change Revenue from Operations 729 740 - 1% 2,230 2,102 6% Total Expenses 564 569 - 1% 1,727 1,620 7% EBITDA* 166 171 - 3% 503 482 5% EBITDA Margin* 22.7% 23.1% - 41 bps 22.6% 22.9% - 35 bps Other Income 30 23 2
Slide 12: Key Balance Sheet Items
Key Balance Sheet Items (All values in ₹ Mn) Particulars 31-Dec-25 30-Sep-25 31-Dec-24 Shareholders Funds 2,657 2,528 2,319 Tangible Assets 6 6 8 Intangibles 798 818 875 Right of Use Assets 72 76 86 Financial Assets (Cash & Equivalents) 1,757 1,604 1,321 Other Non-Current Assets (Net) 32 51 23 Lease
Slide 13: 5-Year journey in a nutshell
5-Year journey in a nutshell Revenue (₹ Mn) Operating EBITDA (₹ Mn)* r ■ -■ - ■ - ■ - ■ - ■ - ■ - ■ - r-•- ■-■-■-■-■, 2,687 579 2,367 2,176 2,087 434 1,879 364 250 191 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 L ■-■-■-■-■-■ J PAT (₹ Mn) Margins built to last r-•- ■-■-■-■-■, •■-■-■-■ -■- · -
Slide 14: The Three-Pronged Growth Strategy
The Three-Pronged Growth Strategy New Product Launch o Niche, Innovation driven o Launch 4-6 products annually, driving market engagement and revenue Coupled with Inorganic strategies along the Volume Growth way o Sales Force Empowerment o Brand acquisitions in current therapies o Targeted training
Slide 15: About the Company
50+ Years Quality and Trust About the Company 12 12
Slide 16: Jagsonpal - Legacy of 'Quality and Trust' since 1964
Jagsonpal - Legacy of ‘Quality and Trust’ since 1964 Deep Market Penetration Quality culture imbibed Enduring Doctor across Operations 100% India Centric Presence across 4000+ Confidence Business towns and cities through CMOs fully complaint with Trusted by >50,000 doctors WHO-GMP and ISO 9001:2015
Slide 17: Strong Presence in Key Therapies
Strong Presence in Key Therapies Gynecology Orthopedics o 7th as per CMARC RPM in CVM o 2nd as per CMARC RPM in CVM o Reaching ~90% of the Gynecologists o Reaching ~80% of the Orthopedists nationwide, engagement with 35,000 out through consistent engagement with of 39,000 gynaecs. 10,000 out of 13,0
Slide 18: Building A High-impact Asset Light Model
Building A High-impact Asset Light Model Capital Intensive Activities - Out-Sourced Ideation Research & Development Contract Manufacturing PAN-India Distribution 0- ~ -- In-house Ideation For Innovative Drug Concepts. Partner with leading Partner with leading 1000+ Medical Reps for 1-2 New Product L
Slide 19: Strategic Pillars
Strategic Pillars Innovation - Niche Large, well Molecules, trained Dominant Market Work Force Share of 1000+ Medical Reps Lean Operations: Inorganic Growth Asset Light Powered by Model Strategic Acquisition 16
Slide 20: Niche Dominators: Our Top Products
Niche Dominators: Our Top 10 Products Indocap, Maintaine Maintaine Key Products Metadec Endoreg Indocap SR Tabs Injections Threatened & Sustained Pain Relief, Endometriosis, Threatened & Habitual Indication Osteoarthritis, Rheumatoid Osteoporosis, Endometriosis Habitual Abortion, Preterm Arthritis,
Slide 21: Niche Dominators: Our Top Products
Niche Dominators: Our Top 10 Products Key Products Lycored SG Lycored Syrup Doxypal DR-L Eukroma Cream Tinilox MPS Treatment Indication Antioxident for Enhances day-to- Helps in the Helps in the of safer day treatment of treatment of Diarrhea pregnancy. immunity bacterial Melasma. and infections. Dy
Slide 22: Execution Excellence across all parameters
Execution Excellence across all parameters Cash Rich and Growth Ready Capital Optimized for scalable growth Rewarding shareholders; Enhanced Payouts 351 - - - 74% + 478% ► 1,456 16.1% I +56% 125 80 139 6.7% 93 252 3.5% FY22 FY25* FY22 FY24 FY25 FY22 FY25 ■ Net Cash Position (₹ Mn) - NWC (₹ Mn) % of
Slide 23: MySakhi Initiative: Where Business Meets Social Impact
MySakhi Initiative Where Business Meets Social Impact Shaping the Future Empowering Women Through MySakhi.in Expanding outreach with self-testing kits, discounted A dedicated website offering educational lab tests, and an online forum to support women’s resources, health tools, and community holisti
Slide 24: Ongoing CSR Initiatives
Ongoing CSR Initiatives Empowering girls through hygiene and education - 14 toilets built across North India, with sanitary support and NGO-led awareness driving dignity and inclusion. 21
Slide 25: Thank You
Thank You Feel free to reach out to us if you have any questions JAGSONPAL PHARMACEUTICALS LTD. Registered Office: Innov8 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi – 110020 cs@jagsonpal.com www.jagsonpal.com +91 124 4406710 INVESTOR RELATIONS Soumya Chhajed Email: soumya@goindiaadvisors.com
Jagsonpal Pharmaceuticals — Q3 FY26 Earnings Presentation on 6ix